

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 August 2008 (21.08.2008)

PCT

(10) International Publication Number
WO 2008/098992 A1

(51) International Patent Classification:
A61K 31/165 (2006.01) **A61P 9/10** (2006.01)

(74) Agent: **DIETEL, Anja**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(21) International Application Number:
PCT/EP2008/051807

(22) International Filing Date:
14 February 2008 (14.02.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07102590.2 16 February 2007 (16.02.2007) EP

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CAMPBELL, Duncan John** [AU/AU]; St. Vincents Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065 (AU). **GILBERT, Richard** [CA/CA]; 23 Annex Lane, Toronto, Ontario ONM5R3V2 (CA). **KELLY, Darren** [AU/AU]; 1-3 Kenilworth Avenue, Wonga Park, Victoria 3115 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(54) Title: USE OF ORGANIC COMPOUNDS

(57) Abstract: The present invention provides methods for the prevention of, delay progression to overt to, or the treatment of diseases modulated by an increase in tissue bradykinin levels, which method comprises administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with e.g. (i) an ACE inhibitor or a pharmaceutically acceptable salt thereof; or (II) an angiotensin II receptor blocker or a pharmaceutically acceptable salt thereof.



WO 2008/098992 A1

Use of Organic Compounds

The natural enzyme renin passes from the kidneys into the blood where it effects the cleavage of angiotensinogen, releasing the decapeptide angiotensin I which is then cleaved in the lungs, the kidneys and other organs to form the octapeptide angiotensin II. The octapeptide increases blood pressure both directly by arterial vasoconstriction and indirectly by liberating from the adrenal glands the sodium-ion-retaining hormone aldosterone, accompanied by an increase in extracellular fluid volume. That increase can be attributed to the action of angiotensin II. Inhibitors of the enzymatic activity of renin bring about a reduction in the formation of angiotensin I. As a result a smaller amount of angiotensin II is produced. The reduced concentration of that active peptide hormone is the direct cause of, e.g., the hypotensive effect of renin inhibitors.

Further evaluations have revealed that renin inhibitors may also be employed for a broader range of therapeutic indications.

It has now surprisingly been found that renin inhibitors, in particular aliskiren, may be employed for prevention of, delay progression to overt to, or the treatment of diseases of the heart, in particular ischaemic heart disease or ischaemic heart damage, due to its ability to increase tissue bradykinin levels. Even more surprisingly, this effect has been shown so far only with ACE inhibitors in high doses (see Hypertension, May 1995; 25: 1014 – 1020) but not other drugs such as NEP inhibitors (see J Pharmacol. Experimental Therapeutics, 1999, vol. 289, No.1, 295-303), whereby this effect of renin inhibitors on bradykinin levels is very robust.

Accordingly, the present invention relates to a method for the prevention of, delay progression to overt to, or the treatment of diseases modulated by an increase in tissue bradykinin levels which method comprises administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof.

Diseases modulated by an increase in tissue bradykinin levels as used herein refers in particular to diseases modulated by an increase in tissue bradykinin levels in the heart. These diseases are treated by, their progression is delayed by or they can be prevented by an increase in tissue bradykinin levels. These are diseases of the heart and can include

effects on the metabolism of the heart and the ability of the cardiomyocyte to withstand ischaemic stress. Typically, the diseases include ischaemic heart disease and ischaemic heart damage. Although the effects of kinins on the heart are not completely understood, they are well documented and are clearly related to therapeutic benefits (see e.g. Spillmann F, Van Linthout S, Schultheiss HP, Tschope C. Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathy. *Curr Opin Nephrol Hypertens* 2006; **15**:22-29; Park SS, Zhao H, Mueller RA, Xu Z. Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. *J Mol Cell Cardiol* 2006; **40**:708-716; Koch M, Spillmann F, Dendorfer A, Westermann D, Altmann C, Sahabi M, Linthout SV, Bader M, Walther T, Schultheiss HP, Tschope C. Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction. *Eur J Pharmacol* 2006; **550**:143-148; Griol-Charhbil V, Messadi-Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, Alhenc-Gelas F, Richer C. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. *Faseb J* 2005; **19**:1172-1174). The potential role of bradykinin in promoting angiogenesis has also been reported (see Peter Gohlke, Ingo Kuwer, Angela Schnell, Kerstin Amann, Gerhard Mall, and Thomas Unger. Blockade of Bradykinin B2 Receptors Prevents the Increase in Capillary Density Induced by Chronic Angiotensin-Converting Enzyme Inhibitor Treatment in Stroke-Prone Spontaneously Hypertensive Rats. *Hypertension*, Jan 1997; **29**: 478 - 482). Promotion of angiogenesis in the heart may be of particular benefit for ischaemic heart disease.

Furthermore, it has now been shown that a combination of a renin inhibitor with an (i) ACE inhibitor or (ii) an angiotensin II receptor blocker confers added or synergistic therapeutic effects over each monotherapy component alone. The preferred combination partner is an ACE inhibitor for this indication.

Accordingly, the present invention further relates to a method for the prevention of, delay progression to overt to, or the treatment of diseases modulated by an increase in tissue bradykinin levels which method comprises administering to a warm-blooded animal a therapeutically effective amount of a combination of a renin inhibitor, or a pharmaceutically acceptable salt thereof, with

- (i) an ACE inhibitor, or a pharmaceutically acceptable salt thereof; or
- (II) an angiotensin II receptor blocker, or a pharmaceutically acceptable salt thereof.

Other objects, features, advantages and aspects of the present invention will become apparent to those skilled in the art from the following description and appended claims. It should be understood, however, that the following description, appended claims, and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following. Abbreviations are those generally known in the art.

Listed below are the definitions of various terms used herein to describe certain aspects of the present invention. However, the definitions and abbreviations thereof used herein are those generally known in the art and apply to the terms as they are used throughout the specification unless they are otherwise limited in specific instances.

The term "prevention" refers to prophylactic administration to healthy patients to prevent the development of the conditions mentioned herein. Moreover, the term "prevention" means prophylactic administration to patients being in a pre-stage of the conditions to be treated.

The term "delay progression to overt to", as used herein, refers to administration to patients being in a pre-stage of the condition to be treated in which patients with a pre-form of the corresponding condition is diagnosed.

The term "treatment" is understood the management and care of a patient for the purpose of combating the disease, condition or disorder.

The term "therapeutically effective amount" refers to an amount of a drug or a therapeutic agent that will elicit the desired biological or medical response of a tissue, system or an animal (including man) that is being sought by a researcher or clinician.

The term "synergistic", as used herein, means that the effect achieved with the methods, combinations and pharmaceutical compositions of the present invention is greater than the sum of the effects that result from individual methods and compositions comprising the active ingredients of this invention separately.

The term "warm-blooded animal or patient" are used interchangeably herein and include, but are not limited to, humans, dogs, cats, horses, pigs, cows, monkeys, rabbits, mice and laboratory animals. The preferred mammals are humans.


The term "pharmaceutically acceptable salt" refers to a non-toxic salt commonly used in the pharmaceutical industry which may be prepared according to methods well-known in the art.

The term "combination" of a renin inhibitor, in particular, aliskiren, and an ACE inhibitor or an angiotensin II receptor blocker, or in each case, a pharmaceutically acceptable salt thereof, means that the components can be administered together as a pharmaceutical composition or as part of the same, unitary dosage form. A combination also includes administering a renin inhibitor, in particular, aliskiren, or a pharmaceutically acceptable salt thereof, and an ACE inhibitor or an angiotensin II receptor blocker, or in each case, a pharmaceutically acceptable salt thereof, each separately but as part of the same therapeutic regimen. The components, if administered separately, need not necessarily be administered at essentially the same time, although they can if so desired. Thus, a combination also refers, for example, administering a renin inhibitor, in particular, aliskiren, or a pharmaceutically acceptable salt thereof, and an ACE inhibitor or an angiotensin II receptor blocker, or in each case, a pharmaceutically acceptable salt thereof, as separate dosages or dosage forms, but at the same time. A combination also includes separate administration at different times and in any order.

The renin inhibitors to which the present invention applies are any of those having renin inhibitory activity *in vivo* and, therefore, pharmaceutical utility, e.g., as therapeutic agents for the prevention of, delay progression to overt to, or the treatment of diseases modulated by an increase in tissue bradykinin levels. In particular, the present invention relates to renin inhibitors disclosed in U.S. Patents No. 5,559,111; No. 6,197,959 and No. 6,376,672.


Renin inhibitors include compounds having different structural features. For example, mention may be made of compounds which are selected from the group consisting of ditekiren (chemical name: [1S-[1R*,2R*,4R*(1R*,2R*)]]-1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-L-phenylalanyl-N-[2-hydroxy-5-methyl-1-(2-methylpropyl)-4-[[[2-methyl-1-[(2-pyridinylmethyl)amino]carbonyl]butyl]amino]carbonyl]hexyl]-N- α -methyl-L-histidinamide); terlakiren (chemical name: [R-(R*,S*)]-N-(4-morpholinylcarbonyl)-L-phenylalanyl-N-[1-(cyclohexylmethyl)-2-hydroxy-3-(1-methylethoxy)-3-oxopropyl]-S-methyl-L-cysteineamide); and zankiren (chemical name: [1S-[1R*[R*(R*)],2S*,3R*]]-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]- α -[[[2-[(4-methyl-1-piperazinyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]-amino]-4-thiazolepropanamide), preferably, in each case, the hydrochloride salt thereof.

Preferred renin inhibitor of the present invention include RO 66-1132 and RO 66-1168 of formulae (I) and (II)



respectively, or in each case, a pharmaceutically acceptable salt thereof.

In particular, the present invention relates to a renin inhibitor which is a δ -amino- γ -hydroxy- ω -aryl-alkanoic acid amide derivative of the formula



wherein R_1 is halogen, C_{1-6} halogenalkyl, C_{1-6} alkoxy- C_{1-6} alkyloxy or C_{1-6} alkoxy- C_{1-6} alkyl; R_2 is halogen, C_{1-4} alkyl or C_{1-4} alkoxy; R_3 and R_4 are independently branched C_{3-6} alkyl; and R_5 is cycloalkyl, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkanoyloxy- C_{1-6} alkyl, C_{1-6} aminoalkyl, C_{1-6} alkylamino- C_{1-6} alkyl, C_{1-6} dialkylamino- C_{1-6} alkyl, C_{1-6} alkanoylamino- C_{1-6} alkyl, $HO(O)C-C_{1-6}$ alkyl, C_{1-6} alkyl- $O-(O)C-C_{1-6}$ alkyl, $H_2N-C(O)-C_{1-6}$ alkyl, C_{1-6} alkyl- $HN-C(O)-C_{1-6}$ alkyl or $(C_{1-6}alkyl)_2N-C(O)-C_{1-6}alkyl$; or a pharmaceutically acceptable salt thereof.

As an alkyl, R_1 may be linear or branched and preferably comprise 1 to 6 C atoms, especially 1 or 4 C atoms. Examples are methyl, ethyl, n- and i-propyl, n-, i- and t-butyl, pentyl and hexyl.

As a halogenalkyl, R_1 may be linear or branched and preferably comprise 1 to 4 C atoms, especially 1 or 2 C atoms. Examples are fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-chloroethyl and 2,2,2-trifluoroethyl.

As an alkoxy, R_1 and R_2 may be linear or branched and preferably comprise 1 to 4 C atoms. Examples are methoxy, ethoxy, n- and i-propyloxy, n-, i- and t-butyloxy, pentyloxy and hexyloxy.

As an alkoxyalkyl, R_1 may be linear or branched. The alkoxy group preferably comprises 1 to 4 and especially 1 or 2 C atoms, and the alkyl group preferably comprises 1 to 4 C atoms. Examples are methoxymethyl, 2-methoxyethyl, 3-methoxypropyl, 4-methoxybutyl, 5-methoxypentyl, 6-methoxyhexyl, ethoxymethyl, 2ethoxyethyl, 3-ethoxypropyl, 4-ethoxybutyl, 5-ethoxypentyl, 6-ethoxyhexyl, propyloxymethyl, butyloxymethyl, 2-propyloxyethyl and 2-butyloxyethyl.

As a C_{1-6} alkoxy- C_{1-6} alkyloxy, R_1 may be linear or branched. The alkoxy group preferably comprises 1 to 4 and especially 1 or 2 C atoms, and the alkyloxy group preferably comprises 1 to 4 C atoms. Examples are methoxymethyloxy, 2-methoxyethyloxy, 3-methoxypropyloxy, 4-methoxybutyloxy, 5-methoxypentyloxy, 6-methoxyhexyloxy, ethoxymethyloxy, 2-ethoxyethyloxy, 3-ethoxypropyloxy, 4-ethoxybutyloxy, 5-ethoxypentyloxy, 6-ethoxyhexyloxy, propyloxymethyloxy, butyloxymethyloxy, 2-propyloxyethyloxy and 2-butyloxyethyloxy.

In a preferred embodiment, R_1 is methoxy- or ethoxy- C_{1-4} alkyloxy, and R_2 is preferably methoxy or ethoxy. Particularly preferred are compounds of formula (III), wherein R_1 is 3-methoxypropyloxy and R_2 is methoxy.

As a branched alkyl, R_3 and R_4 preferably comprise 3 to 6 C atoms. Examples are i-propyl, i- and t-butyl, and branched isomers of pentyl and hexyl. In a preferred embodiment, R_3 and R_4 in compounds of formula (III) are in each case i-propyl.

As a cycloalkyl, R_5 may preferably comprise 3 to 8 ring-carbon atoms, 3 or 5 being especially preferred. Some examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclooctyl. The cycloalkyl may optionally be substituted by one or more substituents, such as alkyl, halo, oxo, hydroxy, alkoxy, amino, alkylamino, dialkylamino, thiol, alkylthio, nitro, cyano, heterocyclyl and the like.

As an alkyl, R_5 may be linear or branched in the form of alkyl and preferably comprise 1 to 6 C atoms. Examples of alkyl are listed herein above. Methyl, ethyl, n- and i-propyl, n-, i- and t-butyl are preferred.

As a C_{1-6} hydroxyalkyl, R_5 may be linear or branched and preferably comprise 2 to 6 C atoms. Some examples are 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 2-, 3- or 4-hydroxybutyl, hydroxypentyl and hydroxyhexyl.

As a C₁₋₆alkoxy-C₁₋₆alkyl, R₅ may be linear or branched. The alkoxy group preferably comprises 1 to 4 C atoms and the alkyl group preferably 2 to 4 C atoms. Some examples are 2-methoxyethyl, 2-methoxypropyl, 3-methoxypropyl, 2-, 3- or 4-methoxybutyl, 2-ethoxyethyl, 2-ethoxypropyl, 3-ethoxypropyl, and 2-, 3- or 4-ethoxybutyl.

As a C₁₋₆alkanoyloxy-C₁₋₆alkyl, R₅ may be linear or branched. The alkanoyloxy group preferably comprises 1 to 4 C atoms and the alkyl group preferably 2 to 4 C atoms. Some examples are formyloxymethyl, formyloxyethyl, acetyloxyethyl, propionyloxyethyl and butyroyloxyethyl.

As a C₁₋₆aminoalkyl, R₅ may be linear or branched and preferably comprise 2 to 4 C atoms. Some examples are 2-aminoethyl, 2- or 3-aminopropyl and 2-, 3- or 4-aminobutyl.


As C₁₋₆alkylamino-C₁₋₆alkyl and C₁₋₆dialkylamino-C₁₋₆alkyl, R₅ may be linear or branched. The alkylamino group preferably comprises C₁₋₄alkyl groups and the alkyl group has preferably 2 to 4 C atoms. Some examples are 2-methylaminoethyl, 2-dimethylaminoethyl, 2-ethylaminoethyl, 2-ethylaminoethyl, 3-methylaminopropyl, 3-dimethylaminopropyl, 4-methylaminobutyl and 4-dimethylaminobutyl.

As a HO(O)C-C₁₋₆alkyl, R₅ may be linear or branched and the alkyl group preferably comprises 2 to 4 C atoms. Some examples are carboxymethyl, carboxyethyl, carboxypropyl and carboxybutyl.

As a C₁₋₆alkyl-O-(O)C-C₁₋₆alkyl, R₅ may be linear or branched, and the alkyl groups preferably comprise independently of one another 1 to 4 C atoms. Some examples are methoxycarbonylmethyl, 2-methoxycarbonylethyl, 3-methoxycarbonylpropyl, 4-methoxycarbonylbutyl, ethoxycarbonylmethyl, 2-ethoxycarbonylethyl, 3-ethoxycarbonylpropyl, and 4-ethoxycarbonylbutyl.

As a H₂N-C(O)-C₁₋₆alkyl, R₅ may be linear or branched, and the alkyl group preferably comprises 2 to 6 C atoms. Some examples are carbamidomethyl, 2-carbamidoethyl, 2-carbamido-2,2-dimethylethyl, 2- or 3-carbamidopropyl, 2-, 3- or 4-carbamidobutyl, 3-carbamido-2-methylpropyl, 3-carbamido-1,2-dimethylpropyl, 3-carbamido-3-ethylpropyl, 3-carbamido-2,2-dimethylpropyl, 2-, 3-, 4- or 5-carbamidopentyl, 4-carbamido-3,3- or -2,2-dimethylbutyl.

Accordingly, preferred are δ -amino- γ -hydroxy- ω -aryl-alkanoic acid amide derivatives of formula (III) having the formula




wherein R_1 is 3-methoxypropyloxy; R_2 is methoxy; and R_3 and R_4 are isopropyl; or a pharmaceutically acceptable salt thereof; chemically defined as 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide, also known as aliskiren.


The term "aliskiren", if not defined specifically, is to be understood both as the free base and as a salt thereof, especially a pharmaceutically acceptable salt thereof, most preferably a hemi-fumarate thereof.

Angiotensin II receptor blockers are understood to be those active agents that bind to the AT_1 -receptor subtype of angiotensin II receptor but do not result in activation of the receptor. As a consequence of the blockade of the AT_1 receptor, these antagonists can, e.g., be employed as antihypertensive agents.


Suitable angiotensin II receptor blockers which may be employed in the combination of the present invention include AT_1 receptor antagonists having differing structural features, preferred are those with the non-peptidic structures. For example, mention may be made of the compounds that are selected from the group consisting of valsartan (EP 443983), losartan (EP253310), candesartan (EP 459136), eprosartan (EP 403159), irbesartan (EP 454511), olmesartan (EP 503785), tasosartan (EP539086), telmisartan (EP 522314), the compound with the designation E-4177 of the formula



the compound with the designation SC-52458 of the following formula



and the compound with the designation the compound ZD-8731 of the formula



or, in each case, a pharmaceutically acceptable salt thereof.

Preferred AT₁-receptor antagonists are those agents that have reach the market, most preferred is valsartan, or a pharmaceutically acceptable salt thereof.

The interruption of the enzymatic degradation of angiotensin I to angiotensin II with ACE inhibitors is a successful variant for the regulation of blood pressure and thus also makes available a therapeutic method for the treatment of hypertension.

A suitable ACE inhibitor to be employed in the combination of the present invention is, e.g., a compound selected from the group consisting alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril, or in each case, a pharmaceutically acceptable salt thereof.

Preferred ACE inhibitors are those agents that have been marketed, most preferred are benazepril and enalapril.

Preferably, a combination according to the present invention comprises a renin inhibitor, e.g., aliskiren, especially in the form of the hemi-fumarate salt thereof, and an ACE inhibitor, e.g., benazepril or enalapril, or an angiotensin II receptor blocker, e.g., valsartan, or in each case, a pharmaceutically acceptable salt thereof.

Most preferred is a combination according to the present invention comprising aliskiren, especially in the form of the hemi-fumarate salt thereof, and valsartan, or a pharmaceutically acceptable salt thereof.

As referred herein above, the compounds to be combined may be present as their pharmaceutically acceptable salts. If these compounds have, e.g., at least one basic center such as an amino group, they can form acid addition salts thereof. Similarly, the compounds having at least one acid group (for example COOH) can form salts with bases.

Corresponding internal salts may furthermore be formed, if a compound comprises, e.g., both a carboxy and an amino group.

The corresponding active ingredients or a pharmaceutically acceptable salts may also be used in form of a solvate, such as a hydrate or including other solvents used, e.g., in their crystallization.

Furthermore, the present invention provides pharmaceutical compositions comprising a renin inhibitor, or a pharmaceutically acceptable salt thereof, preferably aliskiren in the form of the hemi-fumarate salt thereof, and a pharmaceutically acceptable carrier, for the prevention of, delay progression to overt to, or the treatment of diastolic dysfunction or diastolic heart failure.

In another aspect, the present invention further provides pharmaceutical compositions comprising a renin inhibitor, or a pharmaceutically acceptable salt thereof, preferably aliskiren in the form of the hemi-fumarate salt thereof, in combination with

- (i) an ACE inhibitor, preferably benazepril or enalapril, or in each case, a pharmaceutically acceptable salt thereof; or
- (ii) an angiotensin II receptor blocker, preferably valsartan, or a pharmaceutically acceptable salt thereof;

and a pharmaceutically acceptable carrier; for the prevention of, delay progression to overt to, or the treatment of diseases modulated by an increase in tissue bradykinin levels.

As disclosed herein above, a renin inhibitor, in particular, aliskiren, preferably in the form of the hemi-fumarate salt thereof, alone or in combination with an ACE inhibitor, e.g., benazepril or enalapril, or an angiotensin II receptor blocker, e.g., valsartan, or in each case, a pharmaceutically acceptable salt thereof, may be co-administered as a pharmaceutical

composition. The components may be administered together in any conventional dosage form, usually also together with a pharmaceutically acceptable carrier or diluent.

The pharmaceutical compositions according to the invention are those suitable for enteral, such as oral or rectal, transdermal and parenteral administration to mammals, including man. For oral administration the pharmaceutical composition comprising a renin inhibitor, in particular, aliskiren, preferably in the form of the hemi-fumarate salt thereof, alone or in combination with an ACE inhibitor, e.g., benazepril or enalapril, or an angiotensin II receptor blocker, e.g., valsartan, or in each case, a pharmaceutically acceptable salt thereof, can take the form of solutions, suspensions, tablets, pills, capsules, powders, microemulsions, unit dose packets and the like. Preferred are tablets and gelatin capsules comprising the active ingredient together with: a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbants, colorants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.

Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-90%, preferably about 1-80%, of the active ingredient.

The dosage of the active ingredients can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.

Preferred dosages for the active ingredients of the pharmaceutical combinations according to the present invention are therapeutically effective dosages, especially those which are commercially available.

Normally, in the case of oral administration, an approximate daily dose of from about 1 mg to about 360 mg is to be estimated, e.g., for a patient of approximately 75 kg in weight.

For example, the doses of aliskiren to be administered to warm-blooded animals, including man, of approximately 75 kg body weight, especially the doses effective for the inhibition of renin activity, e.g., in lowering blood pressure, are from about 3 mg to about 3 g, preferably from about 10 mg to about 1 g, e.g., from 20 to 200 mg/person/day, divided preferably into 1 to 4 single doses which may, e.g., be of the same size. Usually, children receive about half of the adult dose. The dose necessary for each individual can be monitored, e.g., by measuring the serum concentration of the active ingredient, and adjusted to an optimum level. Single doses comprise, e.g., 75 mg, 150 mg or 300 mg per adult patient.

In case of ACE inhibitors, preferred dosage unit forms of ACE inhibitors are, for example, tablets or capsules comprising e.g. from about 5 mg to about 20 mg, preferably 5 mg, 10 mg, 20 mg or 40 mg, of benazepril; from about 6.5 mg to 100 mg, preferably 6.25 mg, 12.5 mg, 25 mg, 50 mg, 75 mg or 100 mg, of captopril; from about 2.5 mg to about 20 mg, preferably 2.5 mg, 5 mg, 10 mg or 20 mg, of enalapril; from about 10 mg to about 20 mg, preferably 10 mg or 20 mg, of fosinopril; from about 2.5 mg to about 4 mg, preferably 2 mg or 4 mg, of perindopril; from about 5 mg to about 20 mg, preferably 5 mg, 10 mg or 20 mg, of quinapril; or from about 1.25 mg to about 5 mg, preferably 1.25 mg, 2.5 mg, or 5 mg, of ramipril. Preferred is t.i.d. administration.

Angiotensin II receptor blockers, e.g., valsartan, are supplied in the form of a suitable dosage unit form, e.g., a capsule or tablet, and comprising a therapeutically effective amount of an angiotensin II receptor blocker, e.g., from about 20 to about 320 mg of valsartan, which may be applied to patients. The application of the active ingredient may occur up to three times a day, starting, e.g., with a daily dose of 20 mg or 40 mg of an angiotensin II receptor blocker, e.g., valsartan, increasing via 80 mg daily and further to 160 mg daily, and finally up to 320 mg daily. Preferably, an angiotensin II receptor blocker, e.g., valsartan is applied once a day or twice a day with a dose of 80 mg or 160 mg, respectively, each. Corresponding doses may be taken, e.g., in the morning, at mid-day or in the evening.

The above doses encompass a therapeutically effective amount of the active ingredients of the present invention.

Since the present invention relates to methods for the prevention, delay progression to overt to, or the treatment with a combination of compounds which may be administered separately, the invention also relates to combining separate pharmaceutical compositions in a kit form. The kit may comprise, e.g., two separate pharmaceutical compositions: (1) a composition comprising a renin inhibitor, in particular, aliskiren, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent; and (2) a composition comprising an ACE inhibitor, e.g., benazepril or enalapril, or an angiotensin II receptor blocker, e.g., valsartan, or in each case, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. The amounts of (1) and (2) are such that, when co-administered separately a beneficial therapeutic effect(s) is achieved. The kit comprises a container for containing the separate compositions such as a divided bottle or a divided foil packet, wherein each compartment contains a plurality of dosage forms (e.g., tablets) comprising, e.g., (1) or (2). Alternatively, rather than separating the active ingredient-containing dosage forms, the kit may contain separate compartments each of which contains a whole dosage which in turn comprises separate dosage forms. An example of this type of kit is a blister pack wherein each individual blister contains two (or more) tablets, one (or more) tablet(s) comprising a pharmaceutical composition (1), and the second (or more) tablet(s) comprising a pharmaceutical composition (2). Typically the kit comprises directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician. In the case of the instant invention a kit therefore comprises:

- (1) a therapeutically effective amount of a composition comprising a renin inhibitor, in particular, aliskiren, preferably in the form of the hemi-fumarate salt thereof, and a pharmaceutically acceptable carrier or diluent, in a first dosage form;
- (2) a composition comprising an ACE inhibitor, e.g., benazepril or enalapril, or an angiotensin II receptor blocker, e.g., valsartan, or in each case, a pharmaceutically acceptable salt thereof, in an amount such that, following administration, a beneficial therapeutic effect(s) is achieved, and a pharmaceutically acceptable carrier or diluent, in a second dosage form; and
- (3) a container for containing said first and second dosage forms.

The action of a renin inhibitor, e.g., aliskiren, may be demonstrated *inter alia* experimentally by means of *in vitro* tests, the reduction in the formation of angiotensin I being measured in

various systems (human plasma, purified human renin together with synthetic or natural renin substrate).

Since renin displays species specificity for its substrate, human renin inhibitors cannot be efficiently tested in conventional *in vivo* animal models. To circumvent this problem, transgenic rats have been developed harboring either the human renin or the human angiotensinogen genes. Human renin does not effectively cleave rat angiotensinogen and similarly, rat renin cleaves human angiotensinogen poorly. Consequently, the single transgenic rats (i.e., transgenic for either human angiotensinogen or renin) are normotensive. However, when crossbred, the double transgenic (dTGR) offspring develop, e.g., hypertension and diastolic dysfunction, and do not live beyond the 7th or 8th week of age.

A renin inhibitor, e.g., aliskiren, or a pharmaceutically acceptable salt thereof, alone or in combination with an ACE inhibitor, e.g., benazepril or enalapril, or an angiotensin II receptor blocker, e.g., valsartan, or in each case, a pharmaceutically acceptable salt thereof, can be administered by various routes of administration. Each agent can be tested over a wide-range of dosages to determine the optimal drug level for each therapeutic agent alone, or in the specific combination thereof, to elicit the maximal response. For these studies, it is preferred to use treatment groups consisting of at least 6 animals per group. Each study is best performed in away wherein the effects of the combination treatment group are determined at the same time as the individual components are evaluated. Although drug effects may be observed with acute administration, it is preferable to observe responses in a chronic setting. The long-term study is of sufficient duration to allow for the full development of compensatory responses to occur and, therefore, the observed effect will most likely depict the actual responses of the test system representing sustained or persistent effects.

Accordingly, a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with an ACE inhibitor or an angiotensin II receptor blocker, or in each case, a pharmaceutically acceptable salt thereof, can be tested for its effects on bradykinin levels in the double transgenic rats expressing human renin and human angiotensinogen (dTGR). For example, animals may be treated with aliskiren (1 mg/kg/day – 30 mg/kg/day) before the development of disease (prevention design) or after developing the disease (treatment design).

Similarly, a renin inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with an ACE inhibitor or an angiotensin II receptor blocker, or in each case, a

pharmaceutically acceptable salt thereof, may be tested for its effects on bradykinin levels in Ren-2 transgenic rats, expressing the mouse ren-2 (renin) gene. These rats can be made diabetic by injection with streptozotocin and diastolic dysfunction can be induced by ligating (tying off) a coronary artery to induce a myocardial infarction. Over the ensuing ~1 month cardiac fibrosis and diastolic dysfunction develop. For example, animals may be treated with aliskiren (1 mg/kg/day – 60 mg/kg/day) before the development of the disease (prevention design) or after developing the disease (treatment design).

As an example, diabetes is induced in 6 week old female heterozygous transgenic (mRen-2)²⁷ rats by administration of 55 mg/kg streptozotocin diluted in 0.1 citrate buffer, pH 4.5 by tail vein injection. Non-diabetic rats are injected with citrate buffer alone [Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, Skinner SL. Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)²⁷ rats. *Kidney Int* 1999; **56**:211-221.]. Diabetic and non-diabetic rats are randomized to receive either no drug or aliskiren (10 mg/kg/day by osmotic minipump) from 6-7 weeks of age for a duration of 16 weeks. The minipumps are changed every 2 weeks and the amount of aliskiren in the minipumps is adjusted according to the body weight of the rats. Diabetic rats are injected subcutaneously with 2-4 units insulin (Ultratard, Novo Nordisk, Denmark) every second day (3 times a week). If rats have continuously elevated blood glucose levels (>33.3 mmol/L) over a couple of weeks, they are injected with 3 units every day. When glucose levels decrease to 33.3mmol/L they are administered 2-4 units insulin every second day. After 16 weeks drug treatment, rats are anesthetized with ketamine (75mg/kg) and xylazine (10mg/kg) in combination, and blood and tissue is collected for peptide assay. Peptides are measured as previously described [Lawrence AC, Evin G, Kladis A, Campbell DJ. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma. *J Hypertens* 1990; **8**:715-724; Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. *Hypertension* 1991; **18**:763-773; Campbell DJ, Kladis A, Duncan A-M. Nephrectomy, converting enzyme inhibition and angiotensin peptides. *Hypertension* 1993; **22**:513-522; Campbell DJ, Kladis A, Duncan A-M. Bradykinin peptides in kidney, blood, and other tissues of the rat. *Hypertension* 1993; **21**:155-165; Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. *Hypertension* 1994; **23**:439-449; Campbell DJ, Rong P, Kladis A, Rees B, Skinner SL. Angiotensin and bradykinin peptides in the

TGR(mRen-2)27 rat. *Hypertension* 1995; **25**:1014-1020]. Only the left kidney is collected for peptide assay. The heart refers to the cardiac ventricles (both right and left ventricle). The Ang I levels in heart are below the limit of detection of the assay.

There are 4 groups of rats:

1. Non-diabetic control.
2. Non-diabetic administered aliskiren 10 mg/kg/day.
3. Diabetic control.
4. Diabetic administered aliskiren 10 mg/kg/day.

Effect of diabetes: bradykinin peptides

Diabetes has been found to increase BK-(1-9) level in kidney, but does not affect BK-(1-9) level in blood, heart, lung, or brain. Diabetes does not affect BK-(1-7) level or BK-(1-7)/(1-9) ratio in blood or any tissue. BK-(1-9) is an abbreviation for bradykinin-(1-9). Bradykinin-(1-9) is understood to represent the amino acids 1-9 of the bradykinin sequence, which in this case is the complete sequence of bradykinin. BK-(1-7) or Bradykinin-(1-7) is a truncated form of bradykinin and lacks the two C-terminal amino acids.

Effect of aliskiren: bradykinin peptides

Aliskiren has been found to increase both BK-(1-7) and BK-(1-9) levels in heart of both non-diabetic and diabetic rats, with no change in BK-(1-7)/(1-9) ratio. Aliskiren does not affect bradykinin peptides in blood, kidney, lung or brain, although it produces an increase in BK-(1-7)/(1-9) ratio in blood of diabetic, but not non-diabetic, rats.

Effect of aliskiren: bradykinin peptide levels

The increase in BK-(1-7) and BK-(1-9) levels in heart of both non-diabetic and diabetic rats is of interest, and indicates either increased bradykinin peptide formation in this tissue or reduced BK-(1-7) and BK-(1-9) metabolism.

The anti-hypertrophic and cardio-protective actions of the kallikrein kinin system and of bradykinin in both non-diabetic and diabetic animal models are well documented and this suggests for human therapy that they contribute to the therapeutic benefits of aliskiren therapy by e.g. protecting the heart from ischemic, oxidative, inflammatory and/or hemodynamic insult. This tissue-specific effect of aliskiren on cardiac bradykinin peptide levels makes it unlikely that aliskiren will cause angioneurotic edema, either alone or in combination with e.g. an ACE inhibitor.

Summary data: Effect of aliskiren on peptide levels

Tissue	Peptide					
	BK-(1-7)	BK-(1-9)	BK-(1-7)/ (1-9) ratio	Ang II	Ang I	Ang II/ Ang I ratio
Control rats						
Blood	⇒	⇒	⇒	⇒	↓	⇒
Kidney	⇒	⇒	⇒	⇒	↑	↓
Heart	↑	↑	⇒	⇒	ND	ND
Lung	⇒	⇒	⇒	↓	⇒	↓
Brain	⇒	⇒	⇒	↑	⇒	⇒
Diabetic rats						
Blood	⇒	⇒	↑	⇒	⇒	⇒
Kidney	⇒	⇒	⇒	⇒	⇒	↓
Heart	↑	↑	⇒	⇒	ND	ND

- 18 -

Lung	⇒	⇒	⇒	⇒	⇒	⇒
Brain	⇒	⇒	⇒	⇒	⇒	⇒

Heart bradykinin peptides

Group	Mean ± SEM	Dunnett's P
BK-(1-7) (fmol/g)		
Control (n=10)	7.9 ± 1.0	
Control + Aliskiren (n=10)	19.2 ± 2.5	<0.01
Diabetic (n=11)	7.1 ± 0.9	
Diabetic + Aliskiren (n=10)	13.9 ± 1.5	<0.01
BK-(1-9) (fmol/g)		
Control (n=10)	4.9 ± 0.8	
Control + Aliskiren (n=10)	10.6 ± 1.2	<0.01
Diabetic (n=11)	4.1 ± 0.7	
Diabetic + Aliskiren (n=10)	6.4 ± 0.7	<0.05
BK-(1-7)/(1-9) ratio (mol/mol)		
Control (n=10)	1.90 ± 0.27	
Control + Aliskiren (n=10)	1.88 ± 0.18	
Diabetic (n=11)	2.16 ± 0.49	
Diabetic + Aliskiren (n=10)	2.47 ± 0.37	

Effect of diabetes (no drug therapy)

Diabetes did not affect either the BK-(1-7) or BK-(1-9) levels, or the BK-(1-7)/(1-9) ratio.

Effect of drug therapy in control rats

In control rats, aliskiren increased heart BK-(1-7) and BK-(1-9) levels. Drug therapy did not affect the BK-(1-7)/(1-9) ratio.

Effect of drug therapy in diabetic rats

In diabetic rats, aliskiren increased heart BK-(1-7) and BK-(1-9) levels. Drug therapy did not affect the BK-(1-7)/(1-9) ratio.

Furthermore, it has been found that, a combination of a renin inhibitor, e.g., aliskiren, especially in the form of the hemi-fumarate salt thereof, and an ACE inhibitor, e.g., benazepril or enalapril, or an angiotensin II receptor blocker, e.g., valsartan, or in each case, a pharmaceutically acceptable salt thereof, achieves also a therapeutic effect.

It can be shown that combination therapy with a renin inhibitor, e.g., aliskiren, especially in the form of the hemi-fumarate salt thereof, and an ACE inhibitor, e.g., benazepril or enalapril, or an angiotensin II receptor blocker, e.g., valsartan, or in each case, a pharmaceutically acceptable salt thereof, results in an effective therapy for the prevention of, delay progression to overt to, or the treatment of diseases modulated by an increase in tissue bradykinin levels.

The invention furthermore relates to the use of a renin inhibitor, e.g., aliskiren, alone or in combination with an ACE inhibitor, e.g., benazepril or enalapril, or an angiotensin II receptor blocker, e.g., valsartan, or in each case, a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of, delay progression to overt to, or the treatment of diseases modulated by an increase in tissue bradykinin levels.

Accordingly, another embodiment of the present invention relates to the use of a renin inhibitor, e.g., aliskiren, alone or in combination with an ACE inhibitor, e.g., benazepril or enalapril, or an angiotensin II receptor blocker, e.g., valsartan, or in each case, a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of, delay progression to overt to, or the treatment diseases modulated by an increase in tissue bradykinin levels.

The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within

the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore, the Examples herein are to be construed as merely illustrative of certain aspects of the present invention and are not a limitation of the scope of the present invention in any way.

Formulation Example 1:

Composition of aliskiren 150 mg (free base) uncoated tablets in mg/unit.

	Roller compacted tablet	Dosage form 1	Dosage form 2	Dosage form 3
Component				
Aliskiren hemi-fumarate	165.750	165.750	165.750	165.750
Microcrystalline cellulose	220.650	84.750	72.250	107.250
Polyvinylpyrrolidon K 30	-	-	12.000	12.000
Crospovidone	84.000	45.000	44.000	48.200
Aerosil 200	4.800	1.500	1.500	1.800
Magnesium stearate	4.800	3.000	4.500	5.000
Total weight	480.000	300.000	300.000	340.000

Composition of aliskiren 150 mg (free base) uncoated tablets in % by weight.

	Roller compacted tablet	Dosage form 1	Dosage form 2	Dosage form 3
Component				
Aliskiren hemi-fumarate	34.53	55.25	55.25	48.75
Microcrystalline cellulose	45.97	28.25	24.08	31.545
Polyvinylpyrrolidon K 30	-	-	4	3.53
Crospovidone	17.5	15	14.67	14.175
Aerosil 200	1	0.5	0.5	0.53
Magnesium stearate	1	1	1.5	1.47
Total %	100.00	100.00	100.00	100.00

Composition of aliskiren 150 mg (free base) uncoated tablets in mg/unit (divided into inner/outer phase).

			Roller compacted tablet	Dosage form 1	Dosage form 2	Dosage form 3
Component						
Inner Phase	Aliskiren hemi-fumarate	165.75		165.75	165.75	165.75
	Microcrystalline cellulose	220.65		84.75	72.25	90.25
	Polyvinylpyrrolidon K 30	-		-	12.00	12.00
	Crospovidone	36.00		-	-	14.20
	Aerosil 200	-		-	-	-
	Magnesium stearate	2.40		-	-	-
Outer phase	Crospovidone	48.00		45.00	44.00	34.00
	Microcrystalline cellulose	-		-	-	17.00
	Aerosil 200	4.80		1.50	1.50	1.80
	Magnesium stearate	2.40		3.00	4.50	5.00
	Total weight	480.00		300.00	300.00	340.00

Composition of aliskiren 150 mg (free base) uncoated tablets in % by weight (divided into inner/outer phase).

			Roller compacted tablet	Dosage form 1	Dosage form 2	Dosage form 3
Component						
Inner Phase	Aliskiren hemi-fumarate	34.53		55.25	55.25	48.75
	Microcrystalline cellulose	45.97		28.25	24.08	26.545
	Polyvinylpyrrolidon K 30	-		-	4	3.530
	Crospovidone	7.5		-	-	4.175
	Aerosil 200	-		-	-	-
	Magnesium stearate	0.5		-	-	-
Outer phase	Crospovidone	10		15	14.67	10
	Microcrystalline cellulose	-		-	-	5
	Aerosil 200	1		0.5	0.5	0.53
	Magnesium stearate	0.5		1	1.5	1.47
	Total %	100.00		100.00	100.00	100.00

Formulation Example 2:

Composition of aliskiren (dosage form 3) film-coated tablets in mg/unit.

Dosage form 3 / Strength	75 mg (free base)	150 mg (free base)	300 mg (free base)
Component			
Aliskiren hemi-fumarate	82.875	165.750	331.500
Microcrystalline cellulose	53.625	107.250	214.500
Polyvinylpyrrolidon K 30	6.000	12.000	24.000
Crospovidone	24.100	48.200	96.400
Aerosil 200	0.900	1.800	3.600
Magnesium stearate	2.500	5.000	10.000
Total tablet weight	170.000	340.000	680.000
Opadry premix white	9.946	16.711	23.9616
Opadry premix red	0.024	0.238	1.8382
Opadry premix black	0.030	0.051	0.2002
Total fim-coated tablet weight	180.000	357.000	706.000

The dosage forms 1, 2 and 3 may be prepared, e.g., as follows:

- 1) mixing the active ingredient and additives and granulating said components with a granulation liquid;
- 2) drying a resulting granulate;
- 3) mixing the dried granulate with outer phase excipients;
- 4) compressing a resulting mixture to form a solid oral dosage as a core tablet; and
- 5) optionally coating a resulting core tablet to give a film-coated tablet.

The granulation liquid can be ethanol, a mixture of ethanol and water, a mixture of ethanol, water and isopropanol, or a solution of polyvinylpyrrolidones (PVP) in the before mentioned mixtures. A preferred mixture of ethanol and water ranges from about 50/50 to about 99/1 (% w/w), most preferably it is about 94/6 (% w/w). A preferred mixture of ethanol, water and isopropanol ranges from about 45/45/5 to about 98/1/1 (% w/w/w), most preferably from about 88.5/5.5/6.0 to about 91.5/4.5/4.0 (% w/w/w). A preferred concentration of PVP in the

above named mixtures ranges from about 5 to about 30% by weight, preferably from about 15 to about 25%, more preferably from about 16 to about 22%.

Attention is drawn to the numerous known methods of granulating, drying and mixing employed in the art, e.g., spray granulation in a fluidized bed, wet granulation in a high-shear mixer, melt granulation, drying in a fluidized-bed dryer, mixing in a free-fall or tumble blender, compressing into tablets on a single-punch or rotary tablet press.

The manufacturing of the granulate can be performed on standard equipment suitable for organic granulation processes. The manufacturing of the final blend and the compression of tablets can also be performed on standard equipment.

For example, step (1) may be carried out by a high-shear granulator, e.g., Collette Gral; step (2) may be conducted in a fluid-bed dryer; step (3) may be carried out by a free-fall mixer (e.g. container blender, tumble blender); and step (4) may be carried out using a dry compression method, e.g., a rotary tablet press.

Formulation Example 3 (film-coated tablets):

Components	Composition Per Unit (mg)	Standards
Granulation		
Valsartan [= active ingredient]	80.00	
Microcrystalline cellulose/ Avicel PH 102	54.00	NF, Ph. Eur
Crospovidone	20.00	NF, Ph. Eur
Colloidal anhydrous silica / colloidal silicon dioxide / Aerosil 200	0.75	Ph. Eur/NF
Magnesium stearate	2.5	NF, Ph. Eur
Blending		
Colloidal anhydrous silica / colloidal silicon dioxide / Aerosil 200	0.75	Ph. Eur/NF
Magnesium stearate	2.00	NF, Ph. Eur
Coating		
Purified water ^{*)}	-	
DIOLACK pale red 00F34899	7.00	
Total tablet mass	167.00	

^{*)} Removed during processing.

The film-coated tablets may be manufactured, e.g., as follows:

A mixture of valsartan, microcrystalline cellulose, crospovidone, part of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200, silicon dioxide and magnesium stearate is premixed in a diffusion mixer and then sieve through a screening mill. The resulting mixture is again pre-mixed in a diffusion mixer, compacted in a roller compactor and then sieve through a screening mill. To the resulting mixture, the rest of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200 are added and the final blend is made in a diffusion mixer. The whole mixture is compressed in a rotary tableting machine and the tablets are coated with a film by using Diolack pale red in a perforated pan.

Formulation Example 4 (film-coated tablets):

Components	Composition Per Unit (mg)	Standards
Granulation		
Valsartan [= active ingredient]	160.00	
Microcrystalline cellulose/ Avicel PH 102	108.00	NF, Ph. Eur
Crospovidone	40.00	NF, Ph. Eur
Colloidal anhydrous silica / colloidal silicon dioxide / Aerosil 200	1.50	Ph. Eur/NF
Magnesium stearate	5.00	NF, Ph. Eur
Blending		
Colloidal anhydrous silica / colloidal silicon dioxide / Aerosil 200	1.50	Ph. Eur/NF
Magnesium stearate	4.00	NF, Ph. Eur
Coating		
Opadry Light Brown 00F33172	10.00	
Total tablet mass	330.00	

The film-coated tablets are manufactured, e.g., as described in Example 3.

Formulation Example 5 (film-coated tablets):

Components	Composition Per Unit (mg)	Standards
Core: Internal phase		
Valsartan [= active ingredient]	40.00	
Silica, colloidal anhydrous (Colloidal silicon dioxide) [= Glidant]	1.00	Ph. Eur, USP/NF
Magnesium stearate [= Lubricant]	2.00	USP/NF
Crospovidone [Disintegrant]	20.00	Ph. Eur
Microcrystalline cellulose [= Binding agent]	124.00	USP/NF
External phase		
Silica, colloidal anhydrous, (Colloidal silicon dioxide) [= Glidant]	1.00	Ph. Eur, USP/NF
Magnesium stearate [Lubricant]	2.00	USP/NF
Film coating		
Opadry [®] brown OOF 16711 ^{*)}	9.40	
Purified Water ^{**)}	-	
Total tablet mass	199.44	

^{*)} The composition of the Opadry[®] brown OOF16711 coloring agent is tabulated below.

^{**)} Removed during processing.

Opadry[®] Composition:

Ingredient	Approximate % Composition
Iron oxide, black (C.I. No. 77499, E 172)	0.50
Iron oxide, brown (C.I. No. 77499, E 172)	0.50
Iron oxide, red (C.I. No. 77491, E 172)	0.50
Iron oxide, yellow (C.I. No. 77492, E 172)	0.50
Macrogolum (Ph. Eur)	4.00
Titanium dioxide (C.I. No. 77891, E 171)	14.00
Hypromellose (Ph. Eur)	80.00

The film-coated tablets are manufactured, e.g., as described in Example 3.

Formulation Example 6 (capsules):

Components	Composition Per Unit (mg)
Valsartan [= active ingredient]	80.00
Microcrystalline cellulose	25.10
Crospovidone	13.00
Povidone	12.50
Magnesium stearate	1.30
Sodium lauryl sulphate	0.60
Shell	
Iron oxide, red (C.I. No. 77491, EC No. E 172)	0.123
Iron oxide, yellow (C.I. No. 77492, EC No. E 172)	0.123
Iron oxide, black (C.I. No. 77499, EC No. E 172)	0.245
Titanium dioxide	1.540
Gelatin	74.969
Total mass	209.50

The capsules may be manufactured, e.g., as follows:

Granulation/Drying:

Valsartan and microcrystalline cellulose are spray-granulated in a fluidized bed granulator with a granulating solution consisting of povidone and sodium lauryl sulphate dissolved in purified water. The granulate obtained is dried in a fluidized bed dryer.

Milling/Blending:

The dried granulate is milled together with crospovidone and magnesium stearate. The mass is then blended in a conical screw type mixer for approximately 10 minutes.

Encapsulation:

The empty hard gelatin capsules are filled with the blended bulk granules under controlled temperature and humidity conditions. The filled capsules are dedusted, visually inspected, weightchecked and quarantined until by Quality assurance department.

Formulation Example 7 (capsules):

Components	Composition Per Unit (mg)
Valsartan [= active ingredient]	160.00
Microcrystalline cellulose	50.20
Crospovidone	26.00
Povidone	25.00
Magnesium stearate	2.60
Sodium lauryl sulphate	1.20
Shell	
Iron oxide, red (C.I. No. 77491, EC No. E 172)	0.123
Iron oxide, yellow (C.I. No. 77492, EC No. E 172)	0.123
Iron oxide, black (C.I. No. 77499, EC No. E 172)	0.245
Titanium dioxide	1.540
Gelatin	74.969
Total mass	342.00

The capsules are manufactured, e.g., as described in Example 6.

Formulation Example 8 (hard gelatine capsules):

Components	Composition Per Unit (mg)
Valsartan [= active ingredient]	80.00
Sodium laurylsulphate	0.60
Magnesium stearate	1.30
Povidone	12.50
Crospovidone	13.00
Microcrystalline cellulose	21.10
Total mass	130.00

Formulation Example 9 (hard gelatin capsules):


Components	Composition Per Unit (mg)
Valsartan [= active ingredient]	80.00
Microcrystalline cellulose	110.00
Povidone K30	45.20
Sodium laurylsulphate	1.20
Magnesium stearate	2.60
Crospovidone	26.00
Total mass	265.00

Components (1) and (2) are granulated with a solution of components (3) and (4) in water. The components (5) and (6) are added to the dry granulate and the mixture is filled into size 1 hard gelatin capsules.

All publications and patents mentioned herein are incorporate by reference in their entirety as if set forth in full herein.


What is claimed is:

1. A method for the prevention of, delay progression to overt to, or the treatment of diseases modulated by an increase in tissue bradykinin levels which method comprises administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof.
2. A method according to Claim 1, wherein a renin inhibitor is selected from the group consisting of a compound of formula (III)



wherein R_1 is halogen, C_{1-6} -halogenalkyl, C_{1-6} alkoxy- C_{1-6} alkyloxy or C_{1-6} alkoxy- C_{1-6} alkyl; R_2 is halogen, C_{1-4} alkyl or C_{1-4} alkoxy; R_3 and R_4 are independently branched C_{3-6} alkyl; and R_5 is cycloalkyl, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkanoyloxy- C_{1-6} alkyl, C_{1-6} aminoalkyl, C_{1-6} alkylamino- C_{1-6} alkyl, C_{1-6} dialkylamino- C_{1-6} alkyl, C_{1-6} alkanoylamino- C_{1-6} alkyl, $HO(O)C-C_{1-6}$ alkyl, C_{1-6} alkyl- $O-(O)C-C_{1-6}$ alkyl, $H_2N-C(O)-C_{1-6}$ alkyl, C_{1-6} alkyl- $HN-C(O)-C_{1-6}$ alkyl or $(C_{1-6}alkyl)_2N-C(O)-C_{1-6}alkyl$; or in each case a pharmaceutically acceptable salt thereof.


3. A method according to Claim 2, wherein a renin inhibitor is a compound of formula (III) having the formula



wherein R_1 is 3-methoxypropyloxy; R_2 is methoxy; and R_3 and R_4 are isopropyl; or a pharmaceutically acceptable salt thereof.


4. A method according to Claim 3, wherein the compound of formula (IV) is in the form of the hemi-fumarate salt thereof.

5. A method according to any of the preceding claims wherein the disease is selected from ischaemic heart disease and ischaemic heart damage.
6. A pharmaceutical composition comprising a renin inhibitor, or a pharmaceutically acceptable salt thereof, for the prevention of, delay progression to overt to, or the treatment of diseases modulated by an increase in tissue bradykinin levels.
7. A pharmaceutical composition according to Claim 11, wherein a renin inhibitor is a compound of formula (III)



wherein R_1 is halogen, C_{1-6} halogenalkyl, C_{1-6} alkoxy- C_{1-6} alkyloxy or C_{1-6} alkoxy- C_{1-6} alkyl; R_2 is halogen, C_{1-4} alkyl or C_{1-4} alkoxy; R_3 and R_4 are independently branched C_{3-6} alkyl; and R_5 is cycloalkyl, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkanoyloxy- C_{1-6} alkyl, C_{1-6} aminoalkyl, C_{1-6} alkylamino- C_{1-6} alkyl, C_{1-6} dialkylamino- C_{1-6} alkyl, C_{1-6} alkanoylamino- C_{1-6} alkyl, $HO(O)C-C_{1-6}$ alkyl, C_{1-6} alkyl- $O-(O)C-C_{1-6}$ alkyl, $H_2N-C(O)-C_{1-6}$ alkyl, C_{1-6} alkyl- $HN-C(O)-C_{1-6}$ alkyl or $(C_{1-6}alkyl)_2N-C(O)-C_{1-6}alkyl$; or in each case a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition according to Claim 12, wherein a renin inhibitor is a compound of formula (III) having the formula




wherein R_1 is 3-methoxypropyloxy; R_2 is methoxy; and R_3 and R_4 are isopropyl; or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition according to Claim 13, wherein the compound of formula (IV) is in the form of the hemi-fumarate salt thereof.

10. A pharmaceutical composition according to any one of Claims 1 to 9, wherein the disease is selected from ischaemic heart disease and ischaemic heart damage.


11. Use of a renin inhibitor for the manufacture of a medicament for the prevention of, delay progression to overt, or the treatment of diseases modulated by an increase in tissue bradykinin levels.

12. Use according to Claim 17, wherein a renin inhibitor is selected from a compound of the formula



wherein R_1 is halogen, C_{1-6} -halogenalkyl, C_{1-6} -alkoxy- C_{1-6} -alkyloxy or C_{1-6} -alkoxy- C_{1-6} -alkyl; R_2 is halogen, C_{1-4} -alkyl or C_{1-4} -alkoxy; R_3 and R_4 are independently branched C_{3-6} -alkyl; and R_5 is cycloalkyl, C_{1-6} -alkyl, C_{1-6} -hydroxyalkyl, C_{1-6} -alkoxy- C_{1-6} -alkyl, C_{1-6} -alkanoyloxy- C_{1-6} -alkyl, C_{1-6} -aminoalkyl, C_{1-6} -alkylamino- C_{1-6} -alkyl, C_{1-6} -dialkylamino- C_{1-6} -alkyl, C_{1-6} -alkanoylamino- C_{1-6} -alkyl, $HO(O)C-C_{1-6}$ -alkyl, C_{1-6} -alkyl- $O-(O)C-C_{1-6}$ -alkyl, $H_2N-C(O)-C_{1-6}$ -alkyl, C_{1-6} -alkyl- $HN-C(O)-C_{1-6}$ -alkyl or $(C_{1-6}\text{-alkyl})_2N-C(O)-C_{1-6}$ -alkyl; or in each case a pharmaceutically acceptable salt thereof.

13. Use according to Claim 6, wherein a compound of formula (III) has the formula



wherein R_1 is 3-methoxypropyloxy; R_2 is methoxy; and R_3 and R_4 are isopropyl; or a pharmaceutically acceptable salt thereof.

14. Use according to Claim 19, wherein the compound of formula (IV) is in the form of the hemi-fumarate salt thereof.

15. Use according to any of Claims 10 to 14, wherein the disease is selected from ischaemic heart disease and ischaemic heart damage.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/051807

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/165 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/229007 A1 (LEVI ROBERTO [US] ET AL) 11 December 2003 (2003-12-11) the whole document	1-15
X	WO 03/097098 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; FELDMAN DAVID LOUIS [US];) 27 November 2003 (2003-11-27) abstract; claims 2,6 page 3, paragraph 1-4 page 5, paragraph 1	1-15
X	WO 03/035046 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; BUEHLMAYER PETER [CH]; WE) 1 May 2003 (2003-05-01) abstract page 5, paragraph 1 page 8, paragraph 3-5; claims 1,5,12 ----- -/--	1-15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

30 May 2008

Date of mailing of the international search report

06/06/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Jakobs, Andreas

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/051807

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/089729 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; RIGASSI-DIETRICH PETRA GI) 29 September 2005 (2005-09-29) abstract page 13, paragraph 7 - page 14, paragraph 3	1-15
X	----- AZIZI MICHEL: "Renin inhibition" CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, RAPID SCIENCE, LONDON, GB, vol. 15, no. 5, September 2006 (2006-09), pages 505-510, XP008080473 ISSN: 1062-4821 abstract page 393, columns 1-2	1-15
X	----- MAIBAUM J ET AL: "Renin inhibitors as novel treatments for cardiovascular disease" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 13, no. 5, 1 May 2003 (2003-05-01), pages 589-603, XP002327881 ISSN: 1354-3776 the whole document	6-9, 11-14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2008/051807

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-5 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search reportcovers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and; where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 1-5 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: -

Remarks:

Claim 7 is dependent on claim 11,
Claim 8 is dependent on claim 12,
Claim 9 is dependent on claim 13,
Claims 10,15 are dependent on undefined claims,
Claim 12 is dependent on claim 17, however, there is no claim 17
Claim 13 is dependent on claim 6, said claim 6 is not a claim directed to a use.
Claim 14 is dependent on claim 19, however there are no claims 16 to 19.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.2), should the problems which led to the Article 17(2)PCT declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2008/051807

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2003229007	A1	11-12-2003	NONE	
WO 03097098	A	27-11-2003	AU 2003240669 A1	02-12-2003
			BR 0310084 A	15-02-2005
			CA 2485081 A1	27-11-2003
			CN 1655819 A	17-08-2005
			EP 1507558 A1	23-02-2005
			JP 2005526850 T	08-09-2005
			MX PA04011383 A	14-02-2005
			NZ 536555 A	30-03-2007
			RU 2316318 C2	10-02-2008
			ZA 200408442 A	22-02-2006
WO 03035046	A	01-05-2003	AU 2002363087 A1	06-05-2003
			BR 0213357 A	26-10-2004
			CA 2463758 A1	01-05-2003
			CN 1571668 A	26-01-2005
			EP 1448190 A2	25-08-2004
			JP 2005509631 T	14-04-2005
WO 2005089729	A	29-09-2005	AR 048431 A1	26-04-2006
			AU 2005224010 A1	29-09-2005
			BR PI0508833 A	14-08-2007
			CA 2554633 A1	29-09-2006
			CN 1997354 A	11-07-2007
			EP 1729736 A2	13-12-2006
			JP 2007529456 T	25-10-2007
			KR 20070006776 A	11-01-2007